Baya ga shirin wani sabon bugu na kamfen na rigakafin Covid-19 a cikin bazara, Tarayyar Turai ta riga ta tanada ikon samar da sabbin allurar rigakafin "ko da yaushe". gaba Gaggawa na lafiyar jama'a: wannan a matsayin wani ɓangare na abin da ake kira yunƙurin EU FAB a ƙarƙashin ƙungiyar EU ta Ƙirƙirar Shirye-shiryen Ba da Agajin Gaggawa da Hukumar Ba da Amsa Lafiya (HERA).
Hukumar Tarayyar Turai ce ta sanar da tayin jama'a a cikin wannan Afrilu 27th takardun da ta bayyana aniyar ta kai hari ga wadanda har yanzu ba a yi musu allurar ba da yara don rigakafin Covid-19 a cikin bazara.
Hukumar latsa release ya bayyana cewa makasudin yin tallar ita ce:
…domin tanadin iyakoki don kera mRNA, furotin da allurar tushen vector. Wannan zai tanadi sabbin ƙarfin masana'anta don amfani a cikin gaggawar lafiya na gaba. Ana gabatar da takardar ga masu samar da alluran rigakafi tare da wurare a cikin EU/EEA, waɗanda za su iya aika buƙatunsu na shiga har zuwa 3 ga Yuni 2022 16.00 CEST.
Ana samun tayin nan, da takardar gaskiya nan. A sanarwa kafin bayani a kan "Kafa Cibiyar Sadarwar Sadarwar Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararrun Ƙwararru (EU FAB)" an riga an buga shi a watan Satumbar da ya gabata.
Sanarwa mai laushi da takaddun da ke da alaƙa sun ambaci nau'ikan alluran rigakafi guda uku daban-daban: mRNA, furotin, da tushen vector. Amma dangane da martanin da EU ta bayar na Covid-19, a bayyane yake cewa mai yuwuwa za a ba da fifiko ga mRNA.
Kodayake allurar rigakafin cutar Astra-Zeneca da Johnson da Johnson sun kasance wani ɓangare na shirin farko na rigakafin Covid-19 na EU a cikin hunturu 2020/2021, an daina amfani da su kusan shekara guda yanzu.
Sabanin haka, umarnin farko na Hukumar Tarayyar Turai na allurai miliyan 600 na rigakafin BioNTech-Pfizer mRNA (kamar yadda aka rubuta. nan) tun daga lokacin ya haɓaka zuwa jimillar allurai biliyan 2.4 (kamar yadda ake iya gani nan). Hakanan ana ci gaba da amfani da maganin na Moderna mRNA a cikin EU, amma ƙasa da BioNTech-Pfizer.
Hoton da ke ƙasa "Duniyar mu a cikin Bayanai" yana kwatanta wannan fifikon rigakafin mRNA, musamman ma rigakafin BioNTech-Pfizer, a cikin EU.
A watan Disambar da ya gabata, Hukumar Kula da Magunguna ta Turai ta kuma ba da izinin yin amfani da rigakafin tushen furotin na Novavax. Amma kamar yadda jadawali na sama shima ya bayyana a sarari, Novavax da kyar ya sami koma baya a kasuwar EU. (Yawancin allurar rigakafin da aka jera a sama ma EU ba ta ba da izini ba, amma a cikin ƙasashe membobin ɗaya kaɗai.)
Wannan ba abin mamaki ba ne, tunda EMA ta ba da izinin amfani da ita don rigakafin farko, ba a matsayin mai haɓakawa ba, kuma, bisa ga kididdigar hukuma, kusan kashi 85% na manya a cikin EU an riga an yi musu rigakafin.
Sanarwar sanarwar EU FAB game da tanadi "sabuwar halitta Ƙarfin masana'antu" yana iya zama nuni ga BioNTech's 2020 sayayya na Behringwerke samar da makaman a Marburg. Ba kamar abokin kasuwancinta na Pfizer ba, wanda ke tallata rigakafinta a yawancin ƙasashen yammacin duniya, BioNTech a zahiri ba ta da ƙarfin masana'anta kafin siyan ta. Behringwerke, tun kafin a ba da izinin rigakafinta na Covid-19 bai taɓa kawo samfur ba kasuwa.
Taimakon EU FAB ya zo kan diddigin - kuma an ƙirƙira shi a fili - nau'in ɗan Jamus iri ɗaya ne, wanda ya haifar da gwamnatin Jamus ta kammala "kwangilar shirye-shiryen rigakafin cutar" tare da masu ba da kayayyaki biyar a cikin Afrilu. Dukkanin biyar din Jamusawa ne kuma dukkanin biyar suna da hannu wajen samar da alluran rigakafi.
Su ne: BioNTech - a nan ba tare da abokin tarayya na Amurka Pfizer - Curevac tare da haɗin gwiwa tare da GlaxoSmithKline, haɗin gwiwar Jamus / Jamusanci na Wacker da CordenPharma, Celonic, da IDT Dessau. Curevac, wani wanda zai zama mai samar da rigakafin mRNA, shi ma ɗan wasa ne a cikin “tseren” don ƙirƙirar rigakafin Covid-19. Amma, ban da BioNTech da Curevac, yawancin masu karatu ba za su ji labarin sauran ba.
Yawancin masu karatu na Jamus ma ba za su ji su ba. Kamar yadda ÄrzteZeitung, jaridar Jamus ta musamman don MDs, bayanin kula: "Na masu samar da kayayyaki, kawai BioNTech (Comirnaty®)… yana da samfura a kasuwa har yau." Kuma maganin BioNTech, za mu iya ƙarawa, har yanzu yana kan kasuwa ne kawai a Turai a ƙarƙashin “sharadi,” watau gaggawa, izini.
A karkashin kwangilar, gwamnatin Jamus za ta biya masu samar da kayayyaki don tanadin damar samarwa har zuwa (ko, Sakamakon farashin hannun jari na BioNTech, aƙalla) allurai miliyan 80 na alluran rigakafin da ba a fayyace su ba a kowace shekara. Manufar, per sanarwar manema labarai na Maris na Ma'aikatar Lafiya ta Jamus, ita ce tabbatar da samun damar gwamnatin Jamus ga iyawarsu "a cikin yanayin ci gaba da cutar ta Covid-19 ko kuma wata sabuwar annoba."
Bugu da ƙari, sanarwar manema labaru na ma'aikatar ta lura cewa kwangilolin za su taimaka wajen tabbatar da "samar da Jamusanci na alluran rigakafi daga samar da nata." Wannan wani ɗan ƙaramin buri ne dangane da gaskiyar cewa ana buƙatar ƙasashe membobin EU gabaɗaya su karɓi wadatar su na rigakafin Covid-19 ta hanyar kwangilolin da Hukumar Tarayyar Turai ta sasantawa, wanda, kamar yadda aka ambata a sama, ya sami mafi yawan wadatar allurar daidai daga haɗin gwiwar BioNTech-Pfizer.
Manufar rigakafin autarky na Jamus shima baƙon abu ne da ya ci karo da manufar EU na ƙirƙirar "Tarayyar Turai Lafiya,” wanda Hukumar Kula da Shirye-shiryen Ba da Agajin Gaggawa ya kamata ya zama “babban ginshiƙi.” Ma'aikatar Jamus ta bayyana kwangilolin Jamus a matsayin "wanda za a iya faɗaɗawa a duniya," yana mai nuna cewa wasu daga cikin waɗannan kamfanoni na Jamus za su kasance cikin masu karɓar kwangilar matakin EU.
-
Robert Kogon shi ne sunan alkalami na wani ɗan jarida da ake bugawa da yawa wanda ke yin rubuce-rubuce kan al'amuran Turai.
Duba dukkan posts
